CEO’s 2023 AGM presentation (2 months ago):
“Now this one is the Antibody Drug Conjugate I mentioned earlier which is a HER-2 targeted DEP SN38 Antibody Drug Conjugate. I call it Antibody Drug Conjugate, but it’s really just a targeted dendrimer if you like.” ~ previous CEO
Holy cow. What??!!
ADC was mentioned many times in the corresponding presentation slide. But apparently it’s just a targeted dendrimer….
Desperate much?
Another ADC Buyout - Just not SPL, page-16
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.31M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.9¢ | $14.97K | 151.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 372123 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 5042 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| SPL (ASX) Chart |